 |
|
HepCgen genotyping service helps fight Hepatitis C, a 'silent epidemic'
July 22, 2003Southampton UK, July 22, 2003
Genotyping provides route to tailored treatment at lower cost with less side effects
A new centralised genotyping service that enables clinicians to differentiate between types of hepatitis C infections is poised to improve treatment for patients with Hepatitis C, a severely under treated viral infection in the UK. The new service, available through HepCgen will allow clinicians to tailor costly interferon-based treatment regimes to the patients' viral genotype, thus lowering costs and side effects.
Although five times more prevalent than HIV, most cases of Hepatitis C go undetected, prompting the phrase 'the silent epidemic', therefore it is important that, once identified, diagnosis and treatment commence without delay. "HepCgen's centralised Hepatitis C genotyping service allows hospitals throughout the UK extremely rapid access to this important information, without the need for an expensive and time consuming in-house genotyping set up", said Paul Colford, CEO of HepCgen.
Through early identification of patients with genotype 1, or non-1, HepCgen is able to distinguish patients that may require lower doses for shorter periods of time. This knowledge not only has obvious benefits to the patient by reducing medication and associated side effects, but also provides a significant cost saving to healthcare funders: HepCgen founder Dr William Rosenberg estimates a saving to the NHS of half a billion pounds a year if doctors routinely use this service.
HepCgen regards cost of treatment as a significant factor in the number of patients undergoing treatment for Hepatitis C and Dr Rosenberg notes, "Of the 400,000 cases in the UK only about 20,000-30,000 are in secondary care and of those, only some 2,000 cases are being treated, because the NHS won't release funding for treatment."
Further evidence of the importance placed on genotyping in the treatment of hepatitis C came with Roche's announcement on 18th July of the European Commission's approval of a new label for PEGASYS, Roche's flagship treatment for the hepatitis C virus. The approval came as a result of a pivotal study by Roche, demonstrating that the duration of combination therapy and dose of Copegus (ribavirin) for chronic hepatitis C patients depends on viral genotype. Dr. Rosenberg continues, "We have demonstrated similar data with the Schering-Plough therapy, among others. The importance of identifying genotype in the treatment of Hepatitis C is becoming rapidly accepted. This recognition by the European Commission is strong additional testimony."
"HepCgen currently provides its proprietary services to over 20 centres in the UK, most of which are reimbursed by the major pharmaceutical companies involved in Hepatitis C", stated Mr Colford. "We would like to expand our services throughout Europe, as countries like Italy, Germany, and France are treating over five times the number of patients the UK chooses to, and will tremendously benefit by either using HepCgen services or licensing this technology. "
HepCgen Ltd was recently spun out of the University of Southampton and specialises in diagnostics and treatments for chronic liver disease. Dr. Spike Willcocks, IP2IPO adds, "HepCgen is a very exciting opportunity in our portfolio, whose technology meets a now widely recognised medical need, and this step demonstrates the increasing value of the Company. Further development in this area could be rapidly accelerated with additional financing in the near future."
Copy Ends
For more information, please contact:
At the company:
Paul Colford, CEO HepCgen Ltd
023 8079 8945
paul.colford@hepcgen.com
Dr William Rosenberg, University of Southampton
023 8079 6883
wmr@soton.ac.uk
Dr. Spike Willcocks, IP2IPO
Media enquiries:
01865 799 150
spike.wilcocks@ip2ipo.com
Sue Charles, Northbank Communications
020 7886 8152
s.charles@northbankcommunications.com
James Parkinson, Northbank Communications
01260 296506
j.parkinson@northbankcommunications.com
Northbank Communications
Hepatitis Current Events and Hepatitis News RSSChildhood vaccines cause financial burden to many health care providers
The costs that health care providers are charged and reimbursed for childhood vaccines vary widely, and the high cost of some immunizations is leading to significant financial strain for some physicians, according to a pair of new studies from the University of Michigan Health System.
Antibiotics: Single largest class of drugs causing liver injury
Antibiotics are the single largest class of agents that cause idiosyncratic drug-induced liver injury (DILI), reports a new study in Gastroenterology, an official journal of the American Gastroenterological Association (AGA) Institute.
Study unmasks how ovarian tumors evade immune system
Scientists at Johns Hopkins have determined how the characteristic shedding of fatty substances, or lipids, by ovarian tumors allows the cancer to evade the body's immune system, leaving the disease to spread unchecked
Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today reported publication of data in Nature Medicine that supports the broad anti-viral potential of the company's novel anti-phosphatidylserine (anti-PS) antibody platform, showing that its PS-targeting drug bavituximab can cure lethal virus infections in animal disease models.
UT Southwestern researchers develop new strategy for broad spectrum anti-viral drugs
Bavituximab, an anti-viral drug developed by UT Southwestern Medical Center researchers, shows promise as a new strategy to fight viral diseases, including potential bioterrorism agents.
Common cold virus came from birds
A virus that causes cold-like symptoms in humans originated in birds and may have crossed the species barrier around 200 years ago, according to an article published in the December issue of the Journal of General Virology. Scientists hope their findings will help us understand how potentially deadly viruses emerge in humans.
Study finds Canada's supervised injection facility cost-effective
Canada's only supervised injection facility is extending lives and saving the health-care system millions of dollars, a new study shows.
Tibotec presents interim findings for TMC435, an investigational genotype 1 hepatitis C treatment
New clinical data show antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) infection.
Mayo Clinic's new imaging technology accurately identifies a broad spectrum of liver disease
A new study shows that an imaging technology developed by Mayo Clinic researchers can identify liver fibrosis with high accuracy and help eliminate the need for liver biopsies. Liver fibrosis is a common condition that can lead to incurable cirrhosis if not treated in time.
Pakistan introduces vaccine to prevent top child killer
This month, Pakistan is introducing a new combination vaccine that will protect its children against the bacterium Haemophilus influenzae type b (Hib) and four other common childhood diseases.
More Hepatitis Current Events and Hepatitis News Articles
 | Hepatitis C Cookbook: Easy and Delicious Recipes by Heather Jeanne Hepatitis C is a potentially fatal virus that attacks the liver. According to the Centers for Disease Control, Hepatitis C has already infected an estimated four to five million Americans, and worldwide it may have infected as many as 200 million. Most experts agree that if the rate of Hepatitis C infection isn’t curbed soon, it will eventually kill more people each year than AIDS. However,... |
 | Dr. Melissa Palmer's Guide To Hepatitis and Liver Disease by Melissa Palmer In the United States alone, more than four million people are infected with the hepatitis C virus, and chronic liver disease is the twelfth leading cause of death. In this revised and updated edition of her groundbreaking 2000 book, renowned hepatologist Dr. Melissa Palmer discusses all facets of liver disease, from symptoms and tests to treatment options and lifestyle changes. In addition,... |
 | The Hepatitis C Help Book, Revised Edition: A Groundbreaking Treatment Program Combining Western and Eastern Medicine for Maximum Wellness and Healing by Misha Ruth Cohen, Robert Gish, Kalia Doner A fully updated and revised edition of an important health guide, including the latest information on optimum interferon protocol. Hepatitis C has been called "the emergent and preeminent public-health problem of the twenty-first century--surpassing HIV." It has also been dubbed "The Shadow Epidemic," because it is one of the most clandestine of viruses and infects healthy people who have no... |
 | Living with Hepatitis C: A Survivor's Guide, Fourth Edition (Living with) by Gregory T. Everson, Hedy Weinberg "An extremely useful title…recommended."—Library JournalLiving with Hepatitis C was the first book to explain in everyday language the causes of the disease, the major and minor symptoms, and all of the latest treatments, including pegylated interferons. Since its first publication, researchers have made dramatic strides in helping the millions of Americans who suffer from this deadly... |
 | Living With Hepatitis C For Dummies by Nina L. Paul A comprehensive, empathetic guide for anyone suffering from this serious liver disease Approximately 4 million Americans and 170 million people worldwide suffer from hepatitis C, a viral liver disease that is treatable but not curable. It accounts for more than 40 percent of U.S. liver disease deaths–about 8,000 to 10,000 people annually–and is the most common reason for liver... |
 | Triumph Over Hepatitis C by Lloyd Wright This is the third edition, 2nd printing. This edition of Triumph Over Hepatitis C includes all new information updates. It is important for the reader to understand that HCV has not changed, the way to health has not changed. The only thing that has changed is Big Pharm's quest for your money and their complete disregard for your... |
 | The Hepatitis C Handbook by Matthew Dolan This definitive guide explains clearly what Hepatitis C is, outlines the course of the disease and the associated symptoms, and describes how it is transmitted. The author discusses available treatments as well as lifestyle changes that may help. Extensive sections on herbs, vitamins, and nutritional supplements are also... |
 | Living Healthy with Hepatitis C: Natural and Conventional Approaches to Recover Your Quality of Life by Harriet A. Washington As many as four million Americans suffer from the hepatitis C virus (HCV), but most don't even know they're infected. Here at last is the unprecedented book that smashes the myths about the disease as it offers authoritative, lifesaving information you won't find anywhere else. Living Healthy with Hepatitis C is your ultimate weapon against the biggest killer of all: fear. Discover new hope and... |
 | The First Year: Hepatitis C: An Essential Guide for the Newly Diagnosed (First Year, The) by Cara Bruce, Lisa Montanarelli The fifth-year anniversary of the book ushers in a new phase of treatment and information, including protease inhibitors (which have been so successful in treating HIV), split-liver transplants, and prophylactic and therapeutic vaccines for HCV. Bruce and Montanarelli also offer updated information on medications that are toxic to the liver; Eastern and Western approaches to healing; nutrition... |
 | Hepatitis B: The Hunt for a Killer Virus by Baruch S. Blumberg About 375 million people are infected with the hepatitis B virus. It has killed more people than AIDS and also causes millions of cases of liver cancer. The discovery of this deadly virus and the vaccine against it--a vaccine that is sharply decreasing the infection rate worldwide and is probably the first effective cancer vaccine--was one of the great triumphs of twentieth-century medicine. And... |
| © 2008 BrightSurf.com |